NEW YORK--(BUSINESS WIRE)--BioPharm Insight (BPI), the most comprehensive life science market intelligence and analytics solution, today announced the release of its 2016 American Society of Hematology (ASH) Preconference Blood Cancer Report.
The report features industry insights from key opinion leaders on the most impactful abstracts scheduled for ASH’s 58th Annual Meeting December 3-6 in San Diego.
Get the Actionable Report: http://www.biopharminsight.com/ash-2016-preconference-report
“Recent news on patient deaths for a Juno Therapeutics CAR-T (chimeric antigen receptor T-cell) therapy will mean all eyes are even more focused on the nuances that will be discussed about various CAR-T assets during ASH 2016,” said Querida Anderson, BioPharm Insight’s editor in chief. Peak sales estimates for CAR-T therapies are projected to be as high as $10 billion annually, according to BioPharm Insight data.
ASH 2016 will showcase results from registration-directed studies of Novartis’ tisagenlecleucel-T in pediatric lymphoblastic leukemia and Kite Pharma’s KTE-C19 in aggressive non-Hodgkin’s lymphoma. Presentations on data readouts for multiple myeloma, acute myeloid leukemia and myelodysplastic syndrome will also be highly anticipated in the blood cancer space during the meeting.
The full report provides comprehensive analysis of drugs in development by leading life sciences companies for the treatment of blood cancers, including:
- Multiple Myeloma – Novartis, Adaptimmune and GlaxoSmithKline
- Acute Lymphoblastic Leukemia – Juno Therapeutics and Novartis
- Acute Myeloid Leukemia – Astellas, GlycoMimetics, Otsuka and Celgene
- Myelodysplastic Syndrome – Acceleron Pharma, Celgene and Novartis
- Non-Hodgkin’s Lymphoma – Kite Pharma, Roche and Juno
Learn more with BioPharm Insight’s full report: http://www.biopharminsight.com/ash-2016-preconference-report
About BioPharm Insight
BioPharm Insight is the most comprehensive life science market intelligence and analytics solution, featuring a team of investigative journalists writing exclusive news and thousands of healthcare data points, aggregated into one centralized source. In addition to the proprietary articles, BioPharm Insight is currently tracking 500,000 management and R&D contacts, 7,500 biopharma companies with full pipeline data, 120,000 investigational and approved drug profiles, 28,000 M&A and licensing deals, 10,000 extended sales forecasts and epidemiology profiles for hundreds of indications. Meet with BioPharm Insight in person at the 35th Annual J.P. Morgan Conference in January 2017. Learn more at www.biopharminsight.com and follow us: @BioPharmInsight.